Alipogene tiparvovec: gene therapy for lipoprotein lipase deficiency.

Tuesday, 6 November, 2012


Homozygous lipoprotein lipase (LPL) deficiency is an ultra-orphan disease associated with increased rates of pancreatitis.

Current treatments based on acute plasmapheresis allied with ultra-low fat diets are inadequate as responses to fibrates or other triglyceride-lowering therapies tend to be poor. Alipogene tiparvovec is an adeno-associated virus type I (AAV1) gene therapy using a hyper-functional LPL serine(447)-stop (S447X) insert administered intramuscularly under general anaesthetic with allied immunosuppression.

Treatment results in histological muscle expression of LPL allied with a transient 40% reduction in triglycerides and improvements in postprandial chylomicron triglyceride content.

Alipogene tiparvovec is the first possibly curative treatment for LPL deficiency.

Where can I read this paper?

Full article on informa healthcare. Note: you will need the credentials or your institution to login or you can purchase access.

Published: 2013 Jan;13(1):7-10. doi: 10.1517/14712598.2013.738663. Epub 2012 Nov 6.